EVGN · Evogene Ltd. · Metrics
Market Cap
$5.87M
Shares
15.80M
Volume · Oct 20
11.12K
Avg daily vol (3M)
1.41M
EVGN metrics
67 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$0.37
Market cap
$5.87M
Price action
20 metricsPrice change (1W)
-4.8%
Price change (30D)
-19.2%
Price change (3M)
-29.9%
Price change (6M)
-53.6%
Price change (YTD)
-66.2%
Price change (1Y)
-70.5%
Trailing year
Price change (5Y)
—
52-week high
$1.31
52-week low
$0.37
Change from 52-week high
-71.6%
Change from 52-week low
+1.0%
Annualized volatility
79.9%
Annualized volatility (3M)
95.9%
Beta
1.4
RSI (14D)
38.0
Price vs SMA 50
-23.6%
Price vs SMA 200
-46.4%
Avg volume (3M)
1.41M
Relative volume
0.0
Average dollar volume
$624,479
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
15.80M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
3.5×
reciprocal yield 28.2%
P / book
—
FCF yield
-186.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-154.5%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-18
Profitability
9 metricsGross margin
-67.6%
Operating margin
-879.2%
Trailing 12 months
Net margin
-547.6%
Gross profit (TTM)
−$1.12M
Operating profit (TTM)
−$14.57M
Net income (TTM)
−$9.07M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-662.1%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-30.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.66M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+33.8%
Year over year · more shares
Revenue CAGR (3Y)
+32.0%
Revenue CAGR (5Y)
+29.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-67.5%
Debt / equity
—
Current ratio
3.6
EBITDA (TTM)
—
Free cash flow (TTM)
−$10.97M
Quick ratio
3.5
Interest coverage
-2.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$9.32M
Total assets
$13.44M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$10.95M
Capital expenditures (TTM)
$24,000
R&D (TTM)
$7.43M
SG&A (TTM)
—
Stock compensation (TTM)
$201,000
R&D / revenue
448.4%
Stock compensation / revenue
12.1%
Ownership (13F)
9 metrics13F filers
14
13F filer change QoQ
-2
Institutional ownership
1.8%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-46.7%
Holder tenure
2.5
Price vs estimated holder cost
-40.1%
Ownership (registered funds)
1 metricsIndex-fund ownership
0.0%
Short interest
3 metricsShort interest
5.9%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
61 / 100
Insider activity
2 metricsNet insider buying (90D)
$692,100
Insider-sentiment score
90 / 100
Risk flags
1 metricsGoing concern
—